Pardes Biosciences EBIT

As of the most recent data (June 2023), PRDS shows a EBIT of $-83M. That compares with $-75M in the prior-year period — down 9.6% year over year. That is below the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PRDS's EBIT is now $-83M (was $-75M) — a 9.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Pardes Biosciences is outperforming or lagging.

The its sector sector average EBIT is about $-63M. Pardes Biosciences is at $-83M, which is lower that average. That is roughly 32.1% below the sector mean. Use the comparison chart on this page to see how PRDS stacks up against individual peers as well.

Tracking PRDS's ebit over time shows whether Pardes Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-83M That compares with $-75M in the prior-year period — down 9.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Pardes Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-83M) with ownership activity and broader fundamentals.